Short-Term Administration of Disulfiram for Reversal of Latent HIV Infection: A Phase 2 Dose-Escalation Study

The Lancet HIV - United Kingdom
doi 10.1016/s2352-3018(15)00226-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine

British Journal of Cancer
Cancer ResearchOncology
2019English

Human Amnion Cells for the Prevention of Bronchopulmonary Dysplasia: A Protocol for a Phase I Dose Escalation Study

BMJ Open
Medicine
2019English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

Comparison of Reversal With Neostigmine of Low-Dose Rocuronium vs. Reversal With Sugammadex of High-Dose Rocuronium for a Short Procedure

Anaesthesia
AnesthesiologyPain Medicine
2017English

Gene-Expression Reversal of lncRNAs and Associated mRNAs Expression in Active vs Latent HIV Infection

Scientific Reports
Multidisciplinary
2016English

A Phase I Dose-Escalation Study of a Biosimilar Trastuzumab in Chinese Metastasis Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study

Journal of Clinical Pharmacology
Pharmacology
2002English

A Closer Look at the Short-Term Return Reversal

Management Science
Management ScienceManagementOperations ResearchStrategy
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy